Clay Siegall on regulatory
From Founder Stories: Clay Siegall, Co-Founder and CEO of Seattle Genetics · · Axial
“Our first product is called Adcetris and that was approved initially by the FDA in 2011; it's now available in 47 countries including 11 in the last year.”
On , Clay Siegall, Former CEO at Seagen, spoke about regulatory during Founder Stories: Clay Siegall, Co-Founder and CEO of Seattle Genetics on Axial.
About Clay Siegall
Clay Siegall, co-founder and former CEO of Seagen (formerly Seattle Genetics), has described the company's focus on developing antibody-based cancer therapies. In a 2022 talk, he stated that the company's concept is "to make a difference in the life of cancer patients" using antibody drug conjugates. He noted that the company's first product, Adcetris, was approved by the FDA in 2011 and was available in 47 countries as of 2022. Siegall also discussed the company's patient assistance program, CGEN Secure, which he said was created to help with copay costs for patients in the United States and Canada. In a 2020 interview, Siegall discussed the early reception of Padcev, an antibody-drug conjugate for bladder cancer that received FDA approval in December 2019. He stated that the drug was "very active" and that doctors were "embracing it." Siegall reported a 73% objective response rate in a trial combining Padcev with tucatinib for first-line patients, calling the data "spectacular" but noting that larger trials were needed. He also mentioned that the company had submitted tucatinib data to the European Medicines Agency and was nearing approval in several other territories through Project Orbis.